CANCER:

Lung Non-Squamous Non-Small Cell Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Non Small Cell Lung Cancer (2886)

Lung Adenocarcinoma (508)

Lung Non-Small Cell Squamous Cancer (88)

Non Small Cell Lung Cancer (2886)

Lung Adenocarcinoma (508)

Lung Non-Small Cell Squamous Cancer (88)

›

No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week (New A1) toripalimab Sensitive : A1 GlobeNewswire - 1wk	toripalimab Sensitive: A1 - Approval GlobeNewswire - 1 week toripalimab Sensitive : A1 GlobeNewswire - 1 week - (New A1)
STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks (New B) durvalumab + CP-675206 Resistant : B ESMO 2022 - 3wk	durvalumab + CP-675206 Resistant: B - Late Trials ESMO 2022 - 3 weeks durvalumab + CP-675206 Resistant : B ESMO 2022 - 3 weeks - (New B)
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks (New B) atezolizumab Sensitive : B Cancer Med - 3wk	atezolizumab Sensitive: B - Late Trials Cancer Med - 3 weeks atezolizumab Sensitive : B Cancer Med - 3 weeks - (New B)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks (New B) sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3wk	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials ESMO 2022 - 3 weeks sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B ESMO 2022 - 3 weeks - (New B)
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C1 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C1 - Off-label ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C1 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C2 – Inclusion Criteria ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C2 ESMO 2022 - 3 weeks - (New C3)
EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation + PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3wk	bevacizumab + atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks bevacizumab + atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) atezolizumab Sensitive : C3 ESMO 2022 - 3wk	atezolizumab Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks atezolizumab Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) alectinib Sensitive : C3 ESMO 2022 - 3wk	alectinib Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks alectinib Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) MEDI5752 Sensitive : C3 ESMO 2022 - 3wk	MEDI5752 Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks MEDI5752 Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1	pemetrexed Sensitive: A1 - Approval pemetrexed Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1	bevacizumab-awwb Sensitive: A1 - Approval bevacizumab-awwb Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1	bevacizumab + atezolizumab Sensitive: A1 - Approval bevacizumab + atezolizumab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1	bevacizumab Sensitive: A1 - Approval bevacizumab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1	cisplatin + pemetrexed Sensitive: A1 - Approval cisplatin + pemetrexed Sensitive : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval bevacizumab + erlotinib Sensitive : A1	bevacizumab + erlotinib Sensitive: A1 - Approval bevacizumab + erlotinib Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	ALK mutation	Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1	bevacizumab-maly Sensitive: A1 - Approval bevacizumab-maly Sensitive : A1
PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	VC Sensitive: A2 - Guideline VC Sensitive : A2	VC Sensitive: A2 - Guideline VC Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	EP Sensitive: A2 - Guideline EP Sensitive : A2	EP Sensitive: A2 - Guideline EP Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	CaT Sensitive: A2 - Guideline CaT Sensitive : A2	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2	gefitinib Sensitive: A2 - Guideline gefitinib Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	GemVin Sensitive: A2 - Guideline GemVin Sensitive : A2	GemVin Sensitive: A2 - Guideline GemVin Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	GT Sensitive: A2 - Guideline GT Sensitive : A2	GT Sensitive: A2 - Guideline GT Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	GC Sensitive: A2 - Guideline GC Sensitive : A2	GC Sensitive: A2 - Guideline GC Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2	carboplatin + pemetrexed Sensitive: A2 - Guideline carboplatin + pemetrexed Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	GemCarbo Sensitive: A2 - Guideline GemCarbo Sensitive : A2	GemCarbo Sensitive: A2 - Guideline GemCarbo Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2	carboplatin + docetaxel Sensitive: A2 - Guideline carboplatin + docetaxel Sensitive : A2
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2	bevacizumab + atezolizumab Sensitive: A2 - Guideline bevacizumab + atezolizumab Sensitive : A2
PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	PD-L1 expression	Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2	afatinib Sensitive: A2 - Guideline afatinib Sensitive : A2

Lung Non-Squamous Non-Small Cell Cancer

Associations(108)

Associations
(108)